Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
111 results about "Protein recombinants" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
AAV capsid library and AAV capsid proteins
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
AAV capsid library and AAV capsid proteins
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
African swine fever P30 protein recombinant baculovirus expression vector and preparation method thereof
The invention provides African swine fever P30 protein recombinant baculovirus expression vector and a preparation method thereof. The method comprises: amplifying in plasmid PCR-4TOPO-P30 of ASFV (African swine fever virus) P30 full-length gene to obtain P39 gene, linking the amplified P30 gene to a baculovirus vector pFastBac 1 to construct recombinant baculovirus vector pFastBac1-ASFV-P30, converting into competent Escherichia coli cells DH10Bac to obtain recombinant shuttle bacmid rBacmid-ASFV-P30, transfecting to insect cells Sf9 after verification is correct to obtain recombinant baculovirus, and passage amplifying the recombinant baculovirus, linking baculovirus high in titer and containing ASFV P30 gene to High Five insect cells for eukaryotic expression of ASFV P30. The African swine fever P30 protein recombinant baculovirus expression vector is constructed by using the method, a recombinant baculovirus expression system is used to express African swine fever P30 protein in insect cells, and basis is laid for African swine fever ELISA (enzyme-linked-immunosorbent serologic assay) detections.
Owner:QINGDAO AGRI UNIV
Self-assembling recombinant papillomavirus capsid proteins
Recombinant papillomavirus capsid proteins that are capable of self assembly into capsomer structures and viral capsids that comprise conformational antigenic epitopes are provided. The capsomer structures and viral capsids, consisting of the capsid proteins that are expression products of a bovine, monkey or human papillomavirus L1 conformational coding sequence proteins, can be prepared as vaccines to induce a high titer neutralizing antibody response in vertebrate animals. The self assembling capsid proteins can also be used as elements of diagnostic immunoassay procedures for papillomavirus infection.
Owner:DEUTES KREBSFORSCHUNGSZENT THE GERMAN CANCER RES CENT
Recombinant cell surface capture proteins
ActiveUS20140134719A1DifferentiateImprove the level ofAnimal cellsSugar derivativesHeterologousAmino acid substitution
Recombinant cell surface capture proteins and detection molecules that are useful for isolating and detecting cells that produce a secreted heterodimeric protein of interest (POI) that has an immunoglobulin CH3 domain and / or substituted CH3 domain are provided. Recombinant cell surface capture proteins and detection molecules that isolate and detect bispecific antibodies are also provided. The invention also provides recombinant antigen-binding proteins that are capable of recognizing and binding to proteins of interest that contain a CH3 domain and / or a modified CH3 domain, such as a CH3 domain with or without amino acid substitutions at H95 and Y96 (IMGT).
Owner:REGENERON PHARM INC
Recombinant human Mannan-Building Proteins
InactiveUS20060040362A1Peptide/protein ingredientsMicroorganism based processesMannan bindingFiltration
Recombinant Human Mannan-Binding Proteins (rhMBP) having physiological activities which are substantially identical to those offered by Human Mannan-Binding Proteins (hMBP), as well as, in particular, a production system for homogenously producing rhMBP having the specific peaks at the molecular weight of 1,000˜1,300 kDa determined by absorbance (280 nm) in Gel-Filtration Chromatography are provided.
Owner:FUSO PHARMA INDS
Novel coronavirus N protein recombinant antigen and application thereof
ActiveCN111848754AImprove thermal stabilityHigh clinical detection accuracySsRNA viruses positive-senseVirus peptidesAntigenProtein antibody
The invention discloses a novel coronavirus N protein recombinant antigen and application thereof, and belongs to the field of protein immunoassay reagents. The recombinant antigen is a protein, and the amino acid sequence of the recombinant antigen is shown as SEQ ID NO.1 or 3. The recombinant antigen is used for preparing a reagent for detecting an N protein antibody; and compared with an N protein full-length antigen, the thermal stability of the reagent and the detection accuracy can be improved.
Owner:SICHUAN MACCURA BIOTECH CO LTD
Delta opioid receptor protein
InactiveUS20080219925A1Conducive to screeningImmunoglobulinsDrug compositionsΜ-opioid receptorReceptor for activated C kinase 1
Owner:RGT UNIV OF CALIFORNIA
Protein recombinant lactococcus lactis for secretory expression of core antigen COE of PEDV (Porcine Epidemic Diarrhea Virus) as well as preparation method and application of protein recombinant lactococcus lactis
ActiveCN104120142AStrong immune responseGood industry prospectsBacteriaMicroorganism based processesStaphylococcus lactisTGE VACCINE
The invention belongs to the field of animal biomedicine engineering, and in particular discloses protein recombinant lactococcus lactis for secretory expression of a core antigen COE of a PEDV (Porcine Epidemic Diarrhea Virus) as well as a preparation method and an application of the protein recombinant lactococcus lactis. The method comprises the following steps: connecting a signal peptide and other sequences onto a gene of the core antigen COE of the PEDV via an overlap extension PCR method by designing multiple primers, connecting the gene to a lactococcus lactis expression vector pNZ8048 and introducing the vector with the gene into a cell of the lactococcus lactis NZ9000 in an electrotransformation manner so as to obtain recombinant bacteria; and inducing the recombinant bacteria with nisin so as to obtain an expression, and directly taking all induced cultures as oral vaccines capable of stimulating mice and inducing strong cellular immune responses. Thus, the protein recombinant lactococcus lactis can serve as a novel oral vaccine product with a good industrial prospect and has a positive effect for reducing harms of the PEDV to pig industry, thereby playing a great practical significance for promoting the healthy development of the pig industry.
Owner:SOUTH CHINA AGRI UNIV
Truncated echinococcus granulosus EG95 protein recombinant Pichia pastoris high-density fermentation process
InactiveCN102732436ALow cost of expressionHigh expressionFungiMicroorganism based processesGlycerolPichia
The invention discloses a truncated echinococcus granulosus EG95 protein tEG96 recombinant Pichia pastoris high-density fermentation process. The recombinant engineering yeast strain monoclonal EG95-1 employed by the invention is established and identified by the inventor, and is collected in China General Microbiological Culture Collection Center on February 16th, 2012 with a collection number of CGMCC No. 5764. The fermentation method provided by the invention comprises the steps that: a fermentation working seed solution is transferred into a BSM liquid culture medium; the pH value of the culture medium is regulated to 5.5, and enrichment is started; an aqueous solution containing glycerin and PTM 1 is supplemented during the enrichment process; and a solution containing a methanol solution of PTM 1 is separately added into the culture system in stages, such that protein induced expression is carried out.
Owner:LANZHOU INST OF VETERINARY SCI CHINESE ACAD OF AGRI SCI
Preparation method and method of hog cholera-ring-mixed antigen, hog cholera-ring subunit vaccines and preparation method thereof
PendingCN109091669AHigh potencyLow immunogenicitySsRNA viruses positive-senseViral antigen ingredientsAntigenPorcine Circoviruses
The invention provides a preparation method and method of hog cholera-ring-mixed antigen, hog cholera-ring subunit vaccines and a preparation method thereof, and relates to the technical field of biological products. The method comprises the following step of inoculating virus mixing liquid of hog cholera E2 protein recombinant viruses and porcine circovirus II-type Cap protein recombinant virusesinto a cell culture for culturing to obtain the mixed antigen. The preparation method of the hog cholera-ring-mixed antigen, hog cholera-ring subunit vaccines relieves the complicated working procedures that in a conventional technology, two kinds of viruses are cultured in batches and compounded after being gained. The valence of antibody after the vaccines prepared from the mixed antigen are used for vaccine immunity is high.
Owner:TECON BIOLOGY CO LTD
S1 and N double-antigen protein recombinant plasmid capable of expressing IBV (Infectious Bronchitis Virus) and construction method and application thereof
The invention discloses an S1 and N double-antigen protein recombinant plasmid capable of expressing IBV (Infectious Bronchitis Virus) and a construction method and an application thereof. The inventor designs primers according to S1, N and Ub gene sequences of infectious bronchitis virus registered in GenBank, amplifies the S1 and N genes of China isolate GX-YL5 strain of the infectious bronchitis virus and a chicken Ub gene through PCR (Polymerase Chain Reaction), inserts the N and S1 genes of the China isolate GX-YL5 strain of the infectious bronchitis virus and the chicken Ub gene into an eukaryotic expression vector pVAX1 through a molecular biological method, thus constructing an expression plasmid capable of co-expressing the N and S1 genes and the chicken Ub gene and researches DNA vaccine Pvax1-Ub-linker-N-S1. Experiments prove that the vaccine has a significant curative effect of preventing IBV. The S1 and N double-antigen protein recombinant plasmid disclosed by the invention can be used for simultaneously inserting the S1 and N genes of IBV and the chicken Ub gene which are connected in series into the pVAX1 vector to prevent the infectious bronchitis virus.
Owner:GUANGXI UNIV
Application of recombinant human fibroblast growth factor 21 in prevention and treatment of atherosclerosis and related diseases
InactiveCN104667261AFacilitate early diagnosisConducive to disease course interventionPeptide/protein ingredientsBiological testingDiseaseCoronary heart disease
The invention discloses a genetic engineering protein-recombinant human fibroblast growth factor 21 capable of preventing and treating atherosclerosis and related diseases. The recombinant human FGF21 protein obtains patent protection by an applicant (the potential number: ZL200810223501.0). The recombinant human FGF21 protein is capable of effectively relieving and controlling pathogenesis of atherosclerosis by promoting external flow of fat in vascular endothelial cells and reducing accumulation of fat in blood vessel endothelium. Therefore, compared with other listed medicines, the recombinant human FGF21 protein has the advantage that prevention and treatment can be carried out with respect to the sources of atherosclerosis and a coronary heart disease. In addition, through analysis of a lot of clinical data, the inventor discovers that the FGF21 can be applied to auxiliary diagnosis of indexes of the atherosclerosis and the coronary heart disease, and has remarkable correlation in content increase in serum and morbidity of the coronary heart disease. In view of wide action of the recombinant human FGF21 protein in prevention, treatment and diagnosis of the atherosclerosis, the inventor believes that the clinical application value of the recombinant human fibroblast growth factor 21 is great.
Owner:WENZHOU MEDICAL UNIV
Novel recombinant vaccine used for preventing tuberculosis
InactiveCN101850112AStable expressionImproving immunogenicityAntibacterial agentsBacterial antigen ingredientsEscherichia coliImmunogenicity Study
The invention relates to the construction of a human GM-CSF gene and Mycobacterium tuberculosis ESAT6 gene chimerically expressed GMCSF-ESAT6 protein recombinant Bacillus Calmette Guerin (BCG) vaccine and immunogenicity research thereof, namely the sequence of the human GM-CFS gene and the sequence of the Mycobacterium tuberculosis ESAT6 gene are inserted into the sequence of the same escherichiacoli-Mycobacterium tuberculosis shuttle plasmid pMV361 by gene engineering technology so as to construct a recombinant shuttle plasmid rpMV361GMCSF-ESAT6; and a vector is introduced into a BCG vaccine by an electroporation method so as to construct a recombinant BCG vaccine rBCG:GMCSF-ESAT6. The recombinant BCG vaccine can express the human GM-CSF and Mycobacterium tuberculosis ESAT6 gene chimeric protein GMCSF-ESAT6 stably, and has an immunogenicity superior to that of the conventional BCG vaccine. The invention provides a process for preparing the recombinant BCG vaccine, researches the immunity thereof, and belongs to the field of gene engineering and the field of tuberculosis vaccine. The novel recombinant vaccine prevents the generation and the propagration of tuberculosis more effectively.
Owner:SICHUAN UNIV
Vaccine for blocking transmission of echinococcosis pathogeny echinococcus granulosus from source
ActiveCN107510841AIncreased serum titerImprove immunityBacterial antigen ingredientsProtozoa antigen ingredientsMucosal Immune ResponsesMycobacterium smegmatis
The invention discloses a vaccine for blocking transmission of echinococcosis pathogeny echinococcus granulosus from a source. The vaccine provided by the invention is a CTB-EgM123 vaccine or a complete set of vaccine consisting of the CTB-EgM123 vaccine and a subunit vaccine of an EgM123 protein recombinant mycobacterium smegmatis vaccine. An active ingredient of the CTB-EgM123 vaccine is a fusion protein formed by fusion of a cholera toxin B subunit and an echinococcus granulosus EgM123 protein; the active ingredient of the EgM123 protein recombinant mycobacterium smegmatis vaccine can express the recombinant mycobacterium smegmatis of the echinococcus granulosus EgM123 protein. The vaccine provided by the invention can stimulate the immune response in a host, improves the immune level of the host, enhances the intestinal mucosal immune response, and plays an important protective role in resisting infection of echinococcosis.
Owner:THE FIRST TEACHING HOSPITAL OF XINJIANG MEDICAL UNIVERCITY +1
Indirect ELISA assay kit for detecting novel duck reovirus antibody and application of indirect ELISA assay kit
ActiveCN108680744AMonitor the epidemicThe detection method is simpleMaterial analysisProkaryotic expressionReovirus Antibody
The invention discloses an indirect ELISA assay kit for detecting a novel duck reovirus antibody. The kit contains an ELISA plate coated with a novel duck reovirus sigmaC protein recombinant antigen.A preparation method of the novel duck reovirus sigmaC protein recombinant antigen comprises the following steps: taking a complete genome sequence of the duck reovirus with the preservation number ofCCTCC NO:V201818 as a template; amplifying by using a primer pair to obtain sigmaC gene segments; constructing a recombinant expression vector; expressing a duck sigmaC protein recombinant antigen bya prokaryotic expression system. The indirect ELISA assay kit disclosed by the invention can quickly and effectively detect the novel duck reovirus antibody which is newly broken out and takes tarsaljoint swelling as a main symptom so as to monitor epidemic conditions of the novel duck reovirus in a duck plump.
Owner:SHANDONG AGRICULTURAL UNIVERSITY
Preparation method and application of live vector vaccine for expressing duck Tembusu virus (DTMUV) prm and E protein recombinant Newcastle disease virus (NDV)
ActiveCN106520710AReduce detoxificationSsRNA viruses negative-senseSsRNA viruses positive-senseTembusu virusNewcastle disease virus NDV
The invention discloses a preparation method for expressing the duck Tembusu virus (DTMUV) prm and the E protein recombinant Newcastle disease virus (NDV). The preparation method comprises the following steps: 1) constructing full-length plasmids of an attenuated ND GM strain; 2) constructing plasmids for expressing the DTMUV prm and the E protein recombinant NDV; 3) rescuing and identifying the recombinant virus aGM-prm / E. The invention also discloses the virus aGM-prm / E prepared by the method. The virus aGM-prm / E is collected at the China Center for Type Culture Collection (CCTCC), with collection number of CCTCC V201644. A vaccine prepared by utilizing the virus can prevent the ND and the DTMUV disease and conduce to reducing virus removal after virulent NDV infection.
Owner:INST OF ANIMAL HEALTH GUANGDONG ACADEMY OF AGRI SCI +1
Pig cytomegalovirus antibody indirect blocking enzyme-linked immuno sorbent assay (ELISA) detection kit and detection method thereof
The invention discloses a pig cytomegalovirus antibody indirect blocking enzyme-linked immuno sorbent assay (ELISA) detection kit, wherein an antibody detection board, enzyme combination working solution, a blocking antibody, sample diluent, cleaning solution, developing solution A, developing solution B and stop solution are arranged in the kit. A detection board of the kit is a detachable 96-hole elisa plate wrapped by pig cytomegalovirus g B dominant antigen epitope area protein recombinant antigens, enzyme combination working solution is goat anti-rabbit antibody marked by horse radish peroxidase, and the blocking antibody is a rabbit anti-pig cytomegalovirus g B dominant antigen epitope area protein polyclonal antibody. The pig cytomegalovirus antibody indirect blocking ELISA detection kit has the advantages of being strong in specificity, high in sensitivity, easy to operate and suitable for clinical large-scale popularization and application and has wide market prospect.
Owner:SICHUAN AGRI UNIV
Delivery vehicle for recombinant proteins
Recombinant nucleic acid molecules are constructed with a first sequence encoding a transgene under the control of regulatory sequences that direct expression of the transgene product in a hematopoietic stem cell, or a progenitor cell therefrom or cell differentiated therefrom. In one embodiment, the cell which expresses the transgene is a secretory cell. The cell is a megakaryotic progenitor cell, or a cell further differentiated therefrom, such as a platelet. The cell is a granulocyte / macrophage progenitor cell or a cell further differentiated therefrom, such as a mast cell or neutrophils. Such host cells containing the molecule or the molecule itself are employed in methods for treating or preventing infection, inflammation or vascular injuries or any disorders involving or mediated by cells of the hematopoietic lineage.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA +1
Interest protein preparation method and purpose thereof
ActiveCN103131713AHigh expressionEasy to purifyNervous disorderPeptide/protein ingredientsNucleotideHydroxylamine Hydrochloride
The invention relates to an interest protein preparation method and a purpose of the interest protein preparation method. The interest protein preparation method comprises the steps of obtaining interest protein nucleotide sequence fragments, constructing interest protein recombinant expression vectors, expressing interest protein in an inducible mode, purifying the interest protein and cutting purified products. The fronts of the interest protein nucleotide sequence fragments are inserted into monomer cutting recognition sites. Preferably, the upper streams of the interest protein nucleotide sequence fragments are introduced into kex2 enzyme cutting sites, and the down streams of the interest protein nucleotide sequence fragments are introduced into hydroxylamine hydrochloride enzyme cutting sites. The interest protein is obtained through sequence of event (SOE) technology, and is introduced into monomer cutting recognition sites through primers. The interest protein can be human nerve growth factors such as thymosin, tiger stripe pancreatic polypeptide and tiger stripe analgesic peptide. By adopting the interest protein preparation method, obtained interest protein is high in expression quality and easy to purify. Genetic expression products are interest protein monomer, no extra amino acid residue is carried, and thus not only is the good biology activity of interest protein products ensured, but also multicopy cutting cost is saved, the purification is simple and the mass production is facilitated.
Owner:SINOBIOWAY BIOMEDICINE
Self-assembling recombinant papillomavirus capsid proteins
Recombinant papillomavirus capsid proteins that are capable of self assembly into capsomer structures and viral capsids that comprise conformational antigenic epitopes are provided. The capsomer structures and viral capsids, consisting of the capsid proteins that are expression products of a bovine, monkey or human papillomavirus L1 conformational coding sequence proteins, can be prepared as vaccines to induce a high titer neutralizing antibody response in vertebrate animals. The self assembling capsid proteins can also be used as elements of diagnostic immunoassay procedures for papillomavirus infection.
Owner:UNITED STATES OF AMERICA +1
Molecular structure and application of tumor necrosis factor receptor 1 proligand assembly domain glycocluster
The invention belongs to the field of biotechnology and specially relates to a molecular structure, a preparation method and an application of a tumor necrosis factor receptor 1 proligand assembly domain glycocluster. A proligand assembly domain (PLAD) of a tumor necrosis factor receptor 1 and molecules of polyethylene glycol (PEG) and the like are connected through covalent bonds to form a tumor necrosis factor receptor 1 proligand assembly domain protein glycocluster molecule, wherein the PLAD part can be prepared through a technology of protein recombinant and expression. The invention aims at obtaining a PLAD molecule with a long serum half-life period and the PLAD molecule is utilized for treating human inflammatory diseases.
Owner:CHINA PHARM UNIV
Recombinant bacillus subtilis for expressing S protein of transmissible gastroenteritis of swine virus
InactiveCN105886523ABacteriaMicroorganism based processesSwine Transmissible GastroenteritisSpecific immunity
The invention relates to recombinant bacillus subtilis for expressing S protein of transmissible gastroenteritis of swine virus (TGEV), and belongs to the fields of biotechnology and genetic engineering. According to the recombinant bacillus subtilis disclosed by the invention, a TGEV S protein recombinant bacillus subtilis integrated expression plasmid pIncotGSR is successfully constructed, and the expression plasmid is successfully transformed into bacillus subtilis WB800 through electric shock. Based upon Western-blot verification, the TGEV S protein can be successfully expressed in the recombinant bacillus subtilis. An effective TGEV specific immune response level can effectively generate in the body of a one-month-old piglet through stimulation of oral immunization. The recombinant bacillus subtilis is expected to be developed as a genetic engineering oral vaccine for preventing transmissible gastroenteritis of swine.
Owner:NANJING AGRICULTURAL UNIVERSITY
Recombinant modified adenovirus fiber protein
InactiveUS7611868B2Broadening wild-type tropismFunction increaseFibrinogenPeptide/protein ingredientsFiberVaccination
Recombinant adenoviruses comprising modified fiber proteins which expand the tropism of the adenovirus in comparison to wild-type virus are disclosed. The modified fiber proteins described herein contain a peptide ligand for a cell surface binding site other than CAR comprising a 14 amino acid core sequence containing both fixed and variable amino acid residues. The invention includes isolated nucleic acid molecules encoding the modified adenovirus fiber proteins disclosed, as well as recombinant vectors and host cells containing said nucleic acid molecules. Methods of identifying peptide ligands that bind to cell binding sites other than CAR are included comprising screening a phage-display library of peptide ligands expressed within an adenovirus fiber knob context on CAR-negative cells. Recombinant adenoviruses of the present invention will increase the ability of an adenovirus to transduce important cell and tissue targets as part of a gene therapy / gene vaccination regime that have been shown to be refractory to adenoviral infection.
Owner:IST DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI +1
Detection card for rapidly detecting nonstructural protein antibodies of FMDV (foot-and-mouth disease virus) in sera
InactiveCN107870243AQuick checkHigh sensitivitySsRNA viruses positive-senseVirus peptidesAntigenMicrosphere
The invention discloses a detection card for rapidly detecting nonstructural protein antibodies of an FMDV (foot-and-mouth disease virus) in sera. The detection card comprises a detection card housingand a test strip assembled in a detection card housing, wherein the test strip comprises a plastic base plate with a pressure-sensitive adhesive, and a sample pad, a marker pad, a nitrocellulose membrane and absorbent paper are adhered to the base plate in sequence; the marker pad comprises a carrier substrate and a marker, and is a membrane formed by spraying lanthanide fluorescence detection microspheres and lanthanide fluorescence quality control microspheres on the carrier substrate; the nitrocellulose membrane is coated with recombinant protein of FMDV nonstructural protein as a detection line and coated with rabbit anti-chicken lgY antibodies as a control line, and the markers are the fluorescence detection microspheres labeled with FMDV nonstructural protein recombinant antigens and the fluorescence quality control microspheres labeled with chicken lgY antibodies. The detection card can realize rapid detection of the nonstructural protein antibodies of the FMDV on site and in the field and is used for distinguishing virus infection animals from vaccinated animals.
Owner:LANZHOU INST OF VETERINARY SCI CHINESE ACAD OF AGRI SCI +1
Interest protein preparation method and purpose thereof
ActiveCN102978211AKeep aliveReduce cutting costsFermentationAnimals/human peptidesNucleotide sequencingDisulfide bond
Owner:北大未名(合肥)生物制药有限公司
Indirect ELISA detection kit for detecting novel goose astrovirus antibody and application thereof
ActiveCN108956985AMonitor the epidemicThe detection method is simpleMaterial analysisProkaryotic expressionOutbreak
The invention discloses an indirect ELISA detection kit for detecting a novel goose astrovirus antibody. The kit includes an ELISA plate coated with a novel goose astrovirus ORF1b protein recombinantantigen. The preparation method of the novel goose astrovirus ORF1b protein recombinant antigen includes: taking the complete gene sequence of goose astrovirus with a preservation number of CCTCC NO:V201808 as the template, conducting primer pair amplification to obtain an ORF1b gene fragment, constructing a recombinant expression vector, and expressing the goose astrovirus ORF1b protein recombinant antigen by a prokaryotic expression system. The indirect ELISA detection kit provided by the invention can achieve rapid and effective detection of the new outbreak novel goose astrovirus antibodywith gout as the main symptom, thus monitoring the epidemic situation of novel goose astrovirus in a gaggle of geese.
Owner:SHANDONG AGRICULTURAL UNIVERSITY
Expression preparation and application of porcine circovirus type 2 recombinant Cap protein
ActiveCN110981945AHigh expressionSimple purification methodBacteriaViral antigen ingredientsEscherichia coliInclusion bodies
The invention discloses expression preparation and application of porcine circovirus type 2 recombinant Cap protein. The sequence of the porcine circovirus type 2 recombinant Cap protein is the sequence 2 in a sequence table. The coding gene is a sequence 1 in the sequence table. The preparation method of the porcine circovirus type 2 Cap recombinant protein virion comprises the following steps: 1) transforming an escherichia coli BL21 (DE3) competence by expressing a porcine circovirus type 2 Cap recombinant protein recombinant vector to obtain recombinant bacteria for expressing the porcinecircovirus type 2 Cap recombinant protein virion; 2) performing induced expression on the recombinant bacteria, collecting thalli and crushing, and collecting inclusion bodies; 3) dissolving and renaturating the inclusion body to obtain the assembled porcine circovirus type 2 Cap recombinant protein virion. The porcine circovirus type 2 Cap recombinant protein is expressed by adopting an escherichia coli expression system, the protein expression quantity is large, the purification method is simple, the production cost is greatly reduced, and the large-batch production after promotion is facilitated.
Owner:CHINA ANIMAL HUSBANDRY IND
Recombined rhabdovirus AcBac delt CC-GP41 and constructing method thereof
InactiveCN101113460AGood for studying native conformationsQuick Build ActionGenetic engineeringFermentationStructure and functionBio engineering
The invention provides a recombinant baculovirus AcBacDeltaCC-GP41 and an establishment method thereof and relates to the technical field of biological engineering technique and pharmacological. The recombinant baculovirus is CCTCC NO.V200702 and the establishment method comprises the steps: the expression system of Bac-to-Bac baculovirus developed by INVITROGEN Company is used, an AcMNPV baculovirus carrier is selected, then double-deletion shuttle carrier Ac-bacDeltaCC is obtained through a reformation of an AcMNPV shuttle carrier and last the recombinant baculovirus AcBacDeltaCC-GP41 is obtained by using insect cell expression system. The invention has the advantages that the virus is the protein recombinant virus which can high effectively express HIV-1 and has the full length of GP41 and the structure and function thereof are close to natural protein and beneficial for studying natural conformation of GP41 and paves the solid foundation for fully explaining mechanism of HIV-1 entering cells and the immune diagnose and vaccine development based on GP41 and the prevention and curing of AIDS.
Owner:WUHAN INST OF VIROLOGY CHINESE ACADEMY OF SCI
Swine influenza virus H3N2 subtype hemagglutinin (HA)-1 protein recombinant suipoxvirus and preparation method thereof
InactiveCN102154366AObvious blue spotEasy to filterMicroorganism based processesAntiviralsHemagglutininTransfer vector
The invention belongs to the technical field of biology and discloses swine influenza virus H3N2 subtype HA-1 protein recombinant suipoxvirus and a preparation method thereof. An HA1 gene is designed and synthesized according to the gene sequence of HA1 of a A / swine / Guangxi / 1 / 2004(H3N2) strain of the swine influenza virus, and the gene is cloned in a suipoxvirus vector pUSZ11 to obtain a transfer vector pUSZ11 / H3. The recombinant virus is a positive clone obtained by infecting and transfecting PK15 cells with the suipoxvirus and the transfer vector pUSZ11 / H3 and performing homologous recombination. The recombinant suipoxvirus can express HA1 protein stably, and after infection with the virus, the cytopathy becomes regular, the toxic effect of the breeding virus is stabilized at 107TCID50 / mL, the breeding virus can effectively stimulate the immune protect reaction of organisms and can be used in the preparation of medicines for preventing and / or treating infection with swine influenza virus H3N2 subtype.
Owner:NANJING AGRICULTURAL UNIVERSITY
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com